| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03854474 Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475)… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03854474 Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475)… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-05 | NCT04917042 Tazemetostat in Malignant Peripheral Nerve Sheath Tumors |
date change Completion pushed: 2026-04 -> 2026-12 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04224493 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of… | Relapsed/Refractory Follicular Lymphoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06242834 | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell… | B-Cell Non-Hodgkin Lymphoma | Active, Not Recruiting |
| NCT03348631 | Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer | Recurrent Endometrial Endometrioid Adenocarcinoma | Active, Not Recruiting |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| NCT04917042 | Tazemetostat in Malignant Peripheral Nerve Sheath Tumors | Peripheral Nerve Sheath Tumor | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | Prostate Cancer | Recruiting |
| NCT05551936 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline… | Follicular Lymphoma | Active, Not Recruiting |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Atypical Teratoid Rhabdoid Tumor | Active, Not Recruiting |
| NCT03854474 | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475)… | Locally Advanced Urothelial Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT05627232 | Tazemetostat and Palbociclib With CPX-351for R/R AML | Recurrent Acute Myeloid Leukemia | Recruiting |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | Metastatic Prostate Cancer | Active, Not Recruiting |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With… | Recurrent B-Cell Non-Hodgkin Lymphoma | Active, Not Recruiting |
| Not specified | |||
| NCT05228158 | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular… | Lymphoma, Follicular | Active, Not Recruiting |